Candriam Equities L Biotechnology Class R USD CapRegister to Unlock Ratings |
Performance History | 28/02/2025 |
Growth of 1,000 (GBP) | Advanced Graph |
![]() | Fund | -1.0 | 11.8 | 2.0 | 5.3 | 2.1 |
![]() | +/-Cat | 8.0 | 19.6 | 3.3 | 8.3 | 0.8 |
![]() | +/-B’mrk | -1.3 | 9.3 | -5.3 | 11.9 | -2.0 |
Category: Sector Equity Biotechnology | ||||||
Category Benchmark: Morningstar Gbl Biotechnolo... |
Key Stats | ||
NAV 20/03/2025 | USD 270.33 | |
Day Change | -0.69% | |
Morningstar Category™ | Sector Equity Biotechnology | |
ISIN | LU0942225912 | |
Fund Size (Mil) 20/03/2025 | USD 1277.48 | |
Share Class Size (Mil) 20/03/2025 | USD 30.34 | |
Max Initial Charge | 3.50% | |
Ongoing Charge 28/02/2025 | 1.11% |
Morningstar Research |
Analyst Report | 07/03/2025 Jeffrey Schumacher, Director Morningstar, Inc |
An expanding and highly qualified team led by one of the industry’s most seasoned investors in the field, combined with a proven process give this fund an edge. The fund’s cheapest share classes receive a Morningstar Analyst Rating of Silver,... | |
Click here to read this analyst report on the underlying fund. |
Morningstar Pillars | |
---|---|
People | 24 |
Parent | 23 |
Process | 24 |
Performance | |
Price |
Investment Objective: Candriam Equities L Biotechnology Class R USD Cap |
The objective of the sub-fund is to use discretionary management to benefit from the performance of the market in global equities of companies from the biotechnology sector, and to outperform the benchmark. This sub-fund may be appropriate for investors who wish to achieve this objective over a long investment holding period and who are aware of, understand and are able to bear the specific risks of the sub-fund. |
Returns | |||||||||||||
|
Management | ||
Manager Name Start Date | ||
Linden Thomson 29/02/2024 | ||
Servaas Michielssens 30/04/2024 | ||
Inception Date 08/11/2013 |
Advertisement |
Category Benchmark | |
Fund Benchmark | Morningstar Benchmark |
NASDAQ Biotechnology TR USD | Morningstar Gbl Biotechnology NR USD |
Target Market | ||||||||||||||||||||
|
Portfolio Profile for Candriam Equities L Biotechnology Class R USD Cap | 31/01/2025 |
|
|
Top 5 Holdings | Sector | % |
![]() | ![]() | 6.27 |
![]() | ![]() | 5.76 |
![]() | ![]() | 5.53 |
![]() | ![]() | 4.98 |
![]() | ![]() | 4.75 |
![]() | ||
![]() ![]() ![]() | ||
Candriam Equities L Biotechnology Class R USD Cap |